Rangaprasad Sarangarajan, Ph.D.Chief Scientific Officer & SVP at BERG
Rangaprasad (Ranga) Sarangarajan, Ph.D., is the Senior Vice President and Chief Scientific Officer at BERG who oversees all R&D activities and active role in pharmaceutical development and translational sciences strategy development and planning. Dr. Sarangarajan is the co-inventor and co-architect of the BERG Interrogative Biology® technology; currently focused on next generation R&D innovation in the integration of artificial intelligence based analytics, bioinformatics and RWD/RWE utility for speeding up identification/validation of targets, tractability, drug discovery & pharmaceutical development. Dr. Sarangarajan has numerous US and international pending patent applications, covering areas of the discovery platform, cancer, neurology, metabolic diseases, diabetes, obesity and diagnostics. He has published extensively and has presented his research in national and international medical and scientific meetings. He co-authored and co-edited Cellular Respiration and Carcinogenesis, a first of its kind treatise on the role of mitochondrial function and metabolic network regulation in the etiology of cancer as it pertains to the seminal observations made by Otto Warburg. Dr. Sarangarajan has a B.S. in Pharmacy and graduate degree in Pharmaceutical Sciences from the University of Cincinnati College of Pharmacy with focus on pharmacology and toxicology. He went on to pursue post-graduate training in genetics, molecular and cell biology for several years prior to joining Massachusetts College of Pharmacy and Health Sciences (now MCPHS University) and served in capacity of Assistant/Associate Professor.